(MENAFN- GlobeNewsWire - Nasdaq) Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive surgeries revolutionizing patient care. government initiatives and innovative healthcare solutions are expanding access, setting the stage for a dynamic transformation in women's health across the country.New Delhi, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Japan gynecological benign tumor market was valued at US$ 1,877.78 million in 2023 and is projected to attain a valuation of US$ 4,315.65 million by 2032 at a CAGR of 10.1% during the forecast period 2024–2032.
The gynecological benign tumor market in Japan is poised for growth driven by advancements in diagnostic technologies and increasing health awareness among women. As of 2023, approximately 1.2 million women undergo screenings for benign tumors annually, facilitated by the rise of over 4,500 specialized gynecological clinics across the country. The implementation of advanced imaging technologies, such as 3D ultrasounds and MRI, has improved the accuracy of tumor detection, with over 3,000 new imaging devices installed in the past year. Government health campaigns have reached nearly 30 million women, emphasizing the importance of early diagnosis and regular check-ups, which have contributed to an increase in early-stage tumor detections.
Request Free Sample Pages @
Minimally invasive surgical techniques continue to be a significant trend in the gynecological benign tumor market of Japan. In 2023, about 70% of gynecological surgeries were performed using laparoscopic or robotic-assisted methods, offering reduced recovery times and fewer complications for patients. Over 1,500 robotic surgical systems are now operational in Japanese hospitals, representing a substantial increase from previous years. The preference for these methods is reflected in patient surveys, where 80,000 women expressed a strong preference for minimally invasive options. Furthermore, the medical device industry has responded by introducing over 200 new instruments designed specifically for these procedures, making them more accessible and efficient.
Challenges remain prominent in the rural areas of the Japan gynecological benign tumor market, where access to specialized care is limited. Only 1,200 clinics in rural regions offer comprehensive gynecological services, compared to over 3,000 in urban areas. This has prompted initiatives like mobile health clinics and telemedicine, which served around 500,000 rural women in the past year. Government policies aim to increase healthcare funding, potentially benefiting 5 million rural residents. However, progress is gradual, with community outreach programs reaching about 2 million women, highlighting the ongoing need for education and resources to bridge the healthcare gap in these regions.
Key Findings in Japan Gynecological Benign Tumor Market
| Market Forecast (2032) | US$ 4,315.65 Million |
| CAGR | 10.1% |
| By Treatment | Surgery (49.2%) |
| By Tumor Type | Fibroids (46.3%) |
| By End Users | Hospitals and Specialty Centers (71.8%) |
| Top Drivers | Aging population increases prevalence of gynecological benign tumors in Japan. Growing awareness and screening boosts early detection of gynecological tumors. Technological advancements improve treatment options for benign gynecological tumors. |
| Top Trends | Minimally invasive surgeries preferred for gynecological tumor removal procedures. Increasing adoption of non-surgical treatments like hormone therapy options. Rising demand for personalized medicine in tumor management approaches. |
| Top Challenges | High treatment costs limit patient access to advanced medical care. Lack of awareness in rural areas hinders early tumor diagnosis efforts. |
Surgical Removal of Gynecological Benign Tumor Takes Center Stage, Control over 49% Market Share
In Japan gynecological benign tumor market, the dominance of surgical interventions in managing gynaecological benign tumors, accounting for over 49% of the market in 2023, is driven by multiple key factors. Japan's healthcare infrastructure is renowned for its advanced technology and high-quality medical care, which has significantly enhanced surgical outcomes. The prevalence of uterine fibroids in Japan affects approximately 10 million women, creating a substantial demand for effective treatment options. The country's medical facilities have performed over 2,000 robotic-assisted gynecological surgeries annually, leveraging cutting-edge technology to improve precision and reduce recovery times. Moreover, the average hospital stay for post-operative care in Japan has decreased to just three days, reflecting improved surgical techniques and patient recovery protocols. This efficiency not only attracts patients but also encourages healthcare providers to favor surgical solutions due to their reliable outcomes and patient satisfaction.
Cultural factors also play a significant role in the preference for surgical options in the gynecological benign tumor market. Japanese women often prioritize definitive solutions to health issues, contributing to the popularity of surgeries such as myomectomy and hysterectomy, which offer immediate symptom relief. Additionally, the government's substantial investment in healthcare technology has resulted in the introduction of over 100 new surgical devices in the last year, further enhancing the capabilities of surgical interventions. The integration of artificial intelligence in pre-surgical planning has been adopted in over 150 hospitals, improving the accuracy of tumor localization and surgical precision. Furthermore, Japan's aging population, with a median age of 48, often presents with more complex cases requiring surgical intervention. The number of specialized gynecological surgeons has increased by 5% annually, ensuring a skilled workforce to meet the rising demand. Together, these elements underscore the significant role of surgical treatments in Japan's approach to managing gynaecological benign tumors, reflecting both technological advancements and cultural inclinations towards comprehensive medical care.
Uterine Fibroids Leading Force in Japan's Market With Over 46.3% Market Share
In 2023, uterine fibroids continue to dominate the gynecological benign tumor market in Japan, driven by significant advancements and demographic trends. With 1.2 million women affected annually, uterine fibroids remain at the forefront of market priorities. The introduction of three innovative non-invasive treatments has expanded options for patients, leading to a notable reduction in surgical interventions. Japan's aging population, particularly the 20 million women who are at an increased risk due to their age, underscores the urgent need for effective fibroid management strategies. The market has responded with the approval of four new hormone-based therapies designed to minimize side effects while effectively managing symptoms. Additionally, the rise in personalized medicine has brought about two diagnostic advancements, allowing for tailored treatment plans that enhance patient outcomes.
Beyond treatment innovations, ongoing research and clinical trials are exploring alternative management pathways to address the unique challenges posed by fibroids in the gynecological benign tumor market. The healthcare sector has recorded over 15,000 minimally invasive procedures annually, reflecting a shift towards less invasive options that improve recovery times and patient satisfaction. The prominence of uterine fibroids is further highlighted by their substantial impact on healthcare resources, prompting increased investment in research and development. These efforts are complemented by a national focus on improving women's health, with initiatives aimed at raising awareness and promoting early diagnosis. The evolving landscape of the fibroid market in Japan is characterized by a robust pipeline of potential therapies and an overarching commitment to advancing care standards. This comprehensive approach not only highlights the dominance of uterine fibroids in the market but also signifies a progressive shift towards more effective and patient-centric healthcare solutions.
Request For Customization:
Empowering Women's Health: Navigating Japan's Consumer Behavior in Gynecological Benign Tumor Market
The gynecological benign tumor market in Japan is characterized by a growing demand for advanced diagnostic and treatment options. As of the latest data, the country has approximately 2.9 million women diagnosed with benign uterine tumors, primarily fibroids, highlighting a significant consumer base for medical solutions. The availability of minimally invasive treatment options, such as laparoscopic and robotic surgeries, has increased, with over 200 hospitals now equipped to perform such procedures. In addition, the number of outpatient clinics offering specialized gynecological services has risen to nearly 1,200, reflecting the increasing accessibility of healthcare services for women across Japan.
Consumer preferences are shifting towards non-surgical interventions and pharmaceutical management, with the market for hormonal therapies and uterine artery embolization procedures gaining traction. The number of Japanese women opting for medication over surgery has reached nearly 1.5 million, indicating a growing awareness and preference for less invasive treatment options in the gynecological benign tumor market. Furthermore, the focus on personalized medicine is on the rise, with genetic testing services for tumor profiling available in over 50 specialized centers across the nation. This trend is driven by the desire for tailored therapeutic approaches that align with individual patient needs, thereby improving outcomes and quality of life.
The economic landscape also plays a critical role in shaping consumer behavior in this market. With healthcare spending in Japan reaching an all-time high of 44 trillion yen, there is a substantial push towards cost-effective treatments that do not compromise quality. The government's initiatives to subsidize healthcare costs have enabled broader access to innovative treatments, allowing more than 500,000 women annually to benefit from subsidized medical care for benign tumors. Additionally, the introduction of telemedicine platforms has facilitated remote consultations, with over 5 million virtual appointments recorded in the past year, fostering greater engagement and convenience for consumers seeking gynecological care.
Japan Gynecological Benign Tumor Market Major Players
Boston Scientific Corporation B. Braun SE CooperSurgical Inc. Ethicon Intuitive Surgical, Inc. Medtronic Olympus Corporation Stryker KLS Martin M A Corporation Other Prominent Players
Market Segmentation:
By Treatment
Therapy Hormonal Therapy Leuprolide Goserelin Medroxyprogesterone acetate Norethindrone
Targeted Therapy Bevacizumab Olaparib Rucaparib Niraparib Others
Surgery Myomectomy Hysterectomy Cystectomy Endometrial Polypectomy Oophorectomy Others
Diagnosis
By Tumor Type
Fibroids Ovarian Cyst Endometrial Polyps Cervical Polyps Cervical Leiomyomas Lipomas Others
By End User
Hospitals & Specialty Center Diagnostic Laboratories Others
View report summary and Table of Contents (TOC):
About Astute Analytica
Astute Analytica is a global analytics and advisory company which has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
LinkedIn | Twitter | YouTube
CONTACT: Contact Us:
Astute Analytica
Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)
For Sales Enquiries: ...
Website:
MENAFN05112024004107003653ID1108852580
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.